Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) announced the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection (CDI). The research also presented the substantial mortality and frequent complications associated with CDI. Investigator Erik R.

Prana Biotechnology Ltd. (NASDAQ:PRAN)

Prana Biotechnology reported the publication of new data on the ability of PBT2 to repair the damage in an Alzheimer's affected brain thereby facilitating the restoration of cognition in Alzheimer's Disease.